FDA Approves Bepirovirsen as First Functional Cure for Chronic Hepatitis B

For the nearly 300 million people worldwide living with chronic hepatitis B, the standard of care has meant taking a daily antiviral pill for the rest of their lives. On Tuesday, the U.S. Food and Drug Administration authorized the first treatment capable of breaking that lifelong cycle.[1]

The agency approved bepirovirsen, marketed by GSK under the brand name Hibsago, as a functional cure for adults with chronic hepatitis B. The authorization applies specifically to patients without cirrhosis who are already taking standard nucleoside analogue therapy.[1][5]

Until now, available medications could suppress the virus but rarely eliminated it from the bloodstream. Patients who stopped taking their daily pills faced a near-certain rebound of the infection, carrying renewed risks of severe liver damage or hepatocellular carcinoma.[6][7]

Bepirovirsen changes that dynamic by targeting the genetic material of the virus itself. The drug is an antisense oligonucleotide, a type of therapy designed to bind directly to the viral RNA and signal the body's cellular machinery to destroy it.[3][4]

How the therapy works

"This approval marks a milestone for the chronic hepatitis B community," the Hepatitis B Foundation stated following the decision. The organization noted that the therapy brings renewed momentum for screening, diagnosis, and comprehensive liver care.[6]

The treatment works through a dual mechanism that standard antivirals cannot match. First, it halts the production of viral proteins, including the hepatitis B surface antigen, which the virus uses to exhaust and evade the patient's immune system.[2][5]

Second, by clearing those suppressive proteins from the bloodstream, bepirovirsen allows the patient's own immune system to wake up and recognize the infection. This dual action is what enables a sustained response even after the drug is discontinued.[3][5]

In clinical trials, including the pivotal B-Well 1 study, researchers measured success by looking for a "functional cure." This is defined as the sustained absence of the hepatitis B surface antigen and undetectable viral DNA in the blood six months after stopping all treatment.[2][4]

The results demonstrated that up to 26 percent of patients receiving the optimal dosing regimen achieved this functional cure. For those individuals, the virus was suppressed so thoroughly that they no longer required daily antiviral pills to keep their livers healthy.[2][7]

A shift in clinical practice

While a 26 percent success rate means the therapy will not cure everyone, hepatologists view it as a massive leap forward. Previously, the chance of achieving a functional cure on standard nucleoside analogues alone was less than one percent.[3][4]

Clinical data reviewed by the FDA confirmed the breakthrough nature of the regimen. The agency's green light provides a new endpoint for a disease that has historically been managed rather than resolved.[1][7]

The treatment regimen involves a series of subcutaneous injections, administered weekly for 24 weeks. Patients are closely monitored during this period, and those who show a rapid drop in surface antigens are the most likely to achieve long-term viral clearance.[2][5]

GSK has indicated that Hibsago will be available to specialized liver clinics and infectious disease practices in the coming weeks. The company is also continuing to study the drug in combination with other experimental therapies to potentially push the cure rate higher.[4][5]

Monitoring and safety protocols

Because the therapy activates the immune system to attack infected liver cells, patients can experience temporary spikes in liver enzymes. The FDA label requires physicians to monitor liver function closely during the 24-week injection period to prevent severe inflammation.[1][3]

The most common side effects reported during the clinical trials were mild injection site reactions, fatigue, and transient fever. However, the agency restricted the approval to patients without cirrhosis, as those with advanced liver scarring are at higher risk of complications from immune flares.[1][2]

For the global health community, the U.S. approval is expected to accelerate regulatory reviews in Europe and Asia. The burden of chronic hepatitis B is heavily concentrated in the Asia-Pacific region and sub-Saharan Africa, where access to lifelong daily medication remains a profound logistical challenge.[6][7]

Public health advocates are now shifting their focus toward ensuring the new therapy becomes accessible beyond specialized Western clinics. A functional cure that requires only a 24-week intervention could theoretically transform hepatitis B management in low-resource settings.[4][6]

The next critical step will be identifying biomarkers that can predict exactly which patients will respond to the drug. If doctors can determine in advance who falls into the successful 26 percent, they can spare non-responders the cost and side effects of the injections.[2][3]

For now, the introduction of bepirovirsen fundamentally rewrites the conversation between doctors and newly diagnosed patients. A lifelong prescription is no longer the only possible outcome for a chronic hepatitis B infection.[5][7]

Researchers are already looking ahead to the next generation of trials. By combining bepirovirsen with targeted immunotherapies, scientists hope to eventually offer a functional cure to the majority of patients living with the virus.[3][4]